IntroductionIn high-stakes pharmaceutical manufacturing, the chemical integrity of an active pharmaceutical ingredient (API) depends heavily on the purity, structural consistency, and physical stability of its starting intermediates. For targeted oncology drugs—particularly non-steroidal antiandroge
IntroductionIn the fast-moving global fine chemical market, securing a reliable, high-purity supply of core intermediates is vital to commercial success. For enterprise buyers in the pharmaceutical and agrochemical industries, procuring 4-Amino-2-(trifluoromethyl)benzonitrile (CAS No. 654-70-6) pres
IntroductionIn modern oncology, targeted therapies have transformed prostate cancer treatment from broad-spectrum systemic regimes into highly selective molecular interventions. At the center of this revolution is non-steroidal antiandrogen (NSAA) therapy, designed to block androgen receptor signali